Blog
RSS FeedPosted by Michael Wonder on 24 Jan 2018
How excluding some benefits from value assessment of new drugs impacts innovation
23 January 2018 - Payers often assess the benefits of new drugs relative to costs for reimbursement purposes, but they frequently ...
Posted by Michael Wonder on 23 Jan 2018
Competition in pharmaceuticals: more product- than price-oriented?
23 January 2018 - Competition is a subject always open to debate in health care, and pharmaceuticals are no exception, with ...
Posted by Michael Wonder on 23 Jan 2018
EMA surveys pharma companies on their preparedness for Brexit
23 January 2018 - Planning of regulatory steps needed to ensure medicines remain on EU market. ...
Posted by Michael Wonder on 18 Jan 2018
Fed up with drug companies, hospitals decide to start their own
18 January 2018 - A group of large hospital systems plans to create a non-profit generic drug company to battle ...
Posted by Michael Wonder on 12 Jan 2018
Pharma collaborates to improve chances of NICE backing Duchenne drugs
11 January 2018 - A group of pharma companies and Duchenne UK are collaborating to improve the chances of new ...
Posted by Michael Wonder on 05 Jan 2018
Made in China: new and potentially lifesaving drugs
3 January 2018 - One new drug promises to stop cancer from spreading to other organs. Another would treat blood ...
Posted by Michael Wonder on 04 Jan 2018
Several drug makers just raised their prices by nearly 10 percent, and buyers expect more price hikes
2 January 2018 - Several drug makers celebrated the new year with substantial single-digit price hikes, while a new survey ...
Posted by Michael Wonder on 29 Dec 2017
ICER’s guideline on the acceptance and use of “in-confidence” data from manufacturers of pharmaceuticals, devices, and other health care interventions
22 December 2017 - ICER takes its obligations to transparency and fairness seriously. ...
Posted by Michael Wonder on 21 Dec 2017
Drug makers dodged 1.3 billion dollars in payments to Medicaid, report finds
20 December 2017 - Drug makers dodged more than $1.3 billion in Medicaid drug rebates between 2012 and 2016 because ...
Posted by Michael Wonder on 18 Dec 2017
Time for big pharma to step up before the drug price debate rises again
18 December 2017 - In today’s social and political climate, public opinion and public action can galvanise and turn on an ...
Posted by Michael Wonder on 15 Dec 2017
Statement from FDA Commissioner on new FDA efforts to support more efficient development of targeted therapies
15 December 2017 - In recent years, the medical community has experienced a shift in the way health care is ...
Posted by Michael Wonder on 14 Dec 2017
Bumper crop of new drugs fails to lift big pharma R&D returns
14 December 2017 - It is shaping up to be a bumper year for drug approvals, with U.S. officials clearing twice ...
Posted by Michael Wonder on 07 Dec 2017
FDA required studies of approved drugs make a big difference for public health
7 December 2017 - Drugs are approved by FDA based upon substantial evidence from clinical trials that the medicine will be ...
Posted by Michael Wonder on 07 Dec 2017
Speed, safety, and industry funding - from PDUFA I to PDUFA VI
7 December 2017 - The FDA Reauthorization Act of 2017 includes the sixth version of the Prescription Drug User Fee Act. ...
Posted by Michael Wonder on 30 Nov 2017
Advancing medicinal nicotine replacement therapies as new drugs – a new step in FDA’s comprehensive approach to tobacco and nicotine
29 November 2017 - As the leading cause of preventable disease and death in the United States, tobacco causes more than ...